Background
Broadly-neutralizing antibodies (bNAbs) show promise for HIV prevention and treatment. The bispecific antibody 10E8.4/ibalizumab (10E8.4/iMab) has arms that target the HIV-1 envelope membrane proximal external region (10E8.4) and the CD4 receptor on host cells (iMab). It has broad and potent in vitro HIV neutralization ability. We conducted a phase 1b, open label trial of 10E8.4/iMab to assess safety and antiviral effect with and without the CD4 binding site bNAb VRC07-523LS.
Methods
Between October 2023 and April 2025, 20 people with HIV were enrolled at Mbeya Medical Research Center in Tanzania. Participants were ART-naïve or not on ART for >24 weeks, had HIV RNA ≥1000 copies/mL, and CD4 ≥300 cells/µL. They were enrolled sequentially into 5 arms of 4 participants each with bNAbs administered either intravenously (IV) or intramuscularly (IM). The arms were; standard daily oral ART, a single dose of either 10E8.4/iMab at 600mg IV, 600mg IM, 1800mg IV, or a single dose of 10E8.4/iMab 1800mg IV with VRC07-523LS 1200mg IV. Primary endpoints were adverse events (AEs) and change in HIV RNA from day 0 to 14. Arm 2-5 participants started on the same standard daily oral ART after day 14. HIV RNA and serum concentration of 10E8.4/iMab were measured at different time points between day 0 and 14.
Results
Of 117 participants screened, 20 were enrolled, of whom 15 (75.0%) were female with a median age of 28 years (range: 20-45). Participants had a median HIV RNA at enrollment of 38450 copies/mL (range: 2010-667000). Most participants (80%) reported mild to moderate AEs, with 13 (65%) reporting at least one systemic solicited reactogenicity event. There were 2 severe AEs (headache and malaise) and 2 serious AEs (elevated liver transaminases) in arm 3 that resolved without intervention and were deemed unrelated to study products. Antiviral effect was observed in all groups (Figure 1A). The HIV RNA decreased between day 0 and 14 by a median of 38760 copies/mL in arm 1, 16854 in arm 2, 285350 in arm 3, 50833 in arm 4, and 37974 in arm 5 (p=0.205). Conversely, serum 10E8.4/iMab peaked on day 1 and decreased by day 14 (Figure 1B).
Conclusions
10E8.4/iMab administered at various doses, IM or IV, with or without VRC07-523LS, was safe and tolerable with similar antiviral effects to daily oral ART alone.
Table or Figure
